Why might a patient be instructed to take 100 mg aspirin every other day instead of daily?

Alternate-Day Aspirin Dosing: Not a Standard Recommendation

Taking 100 mg aspirin every other day instead of daily is NOT a standard or guideline-recommended approach for cardiovascular disease prevention or treatment. Current evidence-based guidelines consistently recommend daily aspirin dosing (75-100 mg) for both primary and secondary prevention of cardiovascular events 1, 2.

Why This Matters: The Evidence Against Alternate-Day Dosing

Inferior Platelet Inhibition

Research demonstrates that alternate-day aspirin provides significantly less platelet inhibition compared to daily dosing. A randomized crossover study in healthy women found that 100 mg every other day achieved only 12.7% platelet inhibition versus 31.3% with 81 mg daily (P < 0.0001) 3. This translates to:

• 72% of readings showing inadequate platelet inhibition with alternate-day dosing
• Greater day-to-day variability in antiplatelet effect
• Potentially subtherapeutic protection during cardiovascular events

Guideline-Recommended Dosing

All major cardiovascular guidelines specify DAILY aspirin:

• Post-MI or PCI patients: 75-100 mg daily lifelong after initial DAPT period 1
• Chronic coronary syndrome: 75-100 mg daily 1
• Post-CABG: 75-100 mg daily lifelong 1
• Acute coronary syndromes: 75-100 mg daily maintenance after loading dose 2

Possible Explanations for Alternate-Day Dosing

1. Misunderstanding from Women's Health Study

The Women's Health Study used 100 mg every other day for primary prevention and showed stroke reduction but NOT myocardial infarction prevention 3, 4. However:

• This was a primary prevention trial in healthy women
• The alternate-day regimen likely underestimated both efficacy and toxicity of aspirin 3
• This dosing schedule has never been validated for secondary prevention
• Current guidelines do NOT recommend this approach

2. Bleeding Risk Concerns

A patient or provider might attempt to reduce bleeding risk by using alternate-day dosing. However, this is not evidence-based:

• No data supports that alternate-day dosing reduces bleeding while maintaining efficacy
• Proper approach: Use daily 75-100 mg (not higher doses) with gastroprotection (PPI) if high bleeding risk 1
• Consider stopping aspirin entirely if bleeding risk outweighs benefit, rather than using subtherapeutic dosing

3. Cost or Access Issues

Attempting to "stretch" medication supply—though this compromises therapeutic efficacy

4. Patient Non-Adherence or Confusion

Misunderstanding instructions or self-modifying the regimen

Clinical Action Required

If you encounter a patient taking aspirin every other day:

1. Determine the indication:

   • Secondary prevention (prior MI, stroke, PCI, CABG)? → Change to daily dosing immediately 1, 2
   • Primary prevention? → Reassess if aspirin is even indicated per current guidelines 5

2. For secondary prevention patients:

   • Switch to 75-100 mg daily
   • Explain that alternate-day dosing provides inadequate protection
   • If bleeding concerns exist, add PPI rather than reducing aspirin frequency 1

3. For primary prevention:

   • Most patients should NOT be on aspirin at all per 2019 ACC/AHA guidelines 5
   • Consider discontinuation unless patient is 40-70 years old with high ASCVD risk (>10% 10-year risk) and low bleeding risk
   • Even then, daily dosing (not alternate-day) would be appropriate if used

Key Pitfalls to Avoid

• Do not assume alternate-day dosing is "safer"—it simply provides inadequate antiplatelet effect
• Do not continue alternate-day dosing in patients with established cardiovascular disease
• Do not extrapolate Women's Health Study findings to secondary prevention populations
• Do not use alternate-day dosing as a compromise for bleeding concerns—either use daily aspirin with gastroprotection or discontinue aspirin entirely based on risk-benefit assessment

Bottom line: Alternate-day aspirin dosing is a non-standard regimen that likely reflects either outdated practice, patient confusion, or misapplication of primary prevention trial data to inappropriate populations. It should be corrected to guideline-concordant daily dosing or discontinued based on proper indication assessment.